The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2025 | The development and implementation of a novel flow cytometry CD19-agnostic MRD assay in CLL
In this video, Alexey Danilov, MD, PhD, City of Hope, Duarte, CA, briefly comments on the development of a novel flow cytometry CD19-agnostic measurable residual disease (MRD) assay in chronic lymphocytic leukemia (CLL). Prof. Danilov explains that this approach for MRD quantification was needed due to the blocking effect of tafasitamab on CD19, which means conventional MRD assays cannot be used in patients treated with this antibody. This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2025 in Krakow, Poland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, so you know the way this project started is we have this study where we evaluate efficacy of tafasitamab, an anti-CD19 targeting antibody, in combination with zanubrutinib in patients with previously untreated CLL. And we wanted to quantify MRD, but tafasitamab is a target CD19 and actually it blocks the antigen, and many MRD assays are relying on CD19 antibodies in the flow cytometry assay...
Yeah, so you know the way this project started is we have this study where we evaluate efficacy of tafasitamab, an anti-CD19 targeting antibody, in combination with zanubrutinib in patients with previously untreated CLL. And we wanted to quantify MRD, but tafasitamab is a target CD19 and actually it blocks the antigen, and many MRD assays are relying on CD19 antibodies in the flow cytometry assay. So in collaboration with a pathology group we designed an assay which does not necessarily require CD19 antibodies and it uses some other panel of antibodies including CD20, BAFF-R, and others. And this assay has been validated against the standard CD19-based assay in both patients with CLL untreated, as well as in a clinical trial with tafasitamab, where we show it performs really well.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Consulting Fees: Abbvie, ADCT, AstraZeneca, BeiGene, GenMab, Incyte, Janssen, Lilly Oncology, Merck, Nurix, Regeneron, Roche; Ongoing Research Funding: Beigene, GenMab, Incyte, Lilly Oncology, Merck, Nurix, Regeneron.
